Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 0.62 |
| ▸ | CA2 | P00918 | 14/20 | 0.62 |
| ▸ | CA4 | P22748 | 14/20 | 0.62 |
| ▸ | CA9 | Q16790 | 14/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4476835 | 1.00 | CA1 (0.62) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL4471692 | 1.00 | CA1 (0.62) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL4468592 | 0.88 | CA1 (0.50) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL4467575 | 0.88 | CA1 (0.50) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL4465014 | 0.88 | CA1 (0.56) | CA1CA2CA4CA9ABCB1 | |
| SCHEMBL4474944 | 0.88 | DPP4 (0.50) | CA1CA2CA4CA9CNR2 | |
| SCHEMBL4474947 | 0.88 | DPP4 (0.50) | CA1CA2CA4CA9CNR2 | |
| SCHEMBL4475442 | 0.88 | DPP4 (0.50) | CA1CA2CA4CA9CNR2 | |
| SCHEMBL4466251 | 0.87 | CA1 (0.48) | CA1CA2CA4CA9CNR2 | |
| SCHEMBL4466254 | 0.87 | CA1 (0.48) | CA1CA2CA4CA9CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, ARRB1 | CA1 3294/4885CA2 1937/4885CA4 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.